[A25-09] Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2025
Project no.:
A25-09
Commission:
Commission awarded on 22.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor
- Patients with Eastern Cooperative Oncology Group Performance Status 0–1: added benefit not proven
- Patients with Eastern Cooperative Oncology Group Performance Status 2: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-09
| Project no. | Title | Status |
|---|---|---|
| A25-08 | Amivantamab (NSCLC, first line, combination with lazertinib) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-05 | Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-10 | Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V | Commission completed |